Literature DB >> 2328007

Lysophosphatidylcholine: essential role in the inhibition of endothelium-dependent vasorelaxation by oxidized low density lipoprotein.

M Yokoyama1, K Hirata, R Miyake, H Akita, Y Ishikawa, H Fukuzaki.   

Abstract

Endothelial cells are known to play an important role in the regulation of vascular tone. Here we demonstrate that modified low density lipoprotein (LDL) with copper oxidation or phospholipase A2 treatment elicits a potent inhibitory action on endothelium-dependent relaxations evoked by acetylcholine, although native LDL does not affect endothelium-dependent relaxations. Phosphatidylcholine of native LDL is converted to lysophosphatidylcholine during these modifications. Furthermore, lysophosphatidylcholine fraction separated from oxidized LDL (0.5mg.protein/ml) by thin layer chromatography abolished endothelium-dependent relaxations, although the remaining lipid fraction had little effects on endothelium-dependent relaxations. These results indicate that lysophosphatidylcholine is the principal substance for the impairment of endothelium-dependent relaxations by oxidized LDL and phospholipase A2 treated LDL.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2328007     DOI: 10.1016/0006-291x(90)91708-z

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  22 in total

Review 1.  Lipids and endothelium-dependent vasodilation--a review.

Authors:  Lars Lind
Journal:  Lipids       Date:  2002-01       Impact factor: 1.880

Review 2.  Role of oxidized human plasma low density lipoproteins in atherosclerosis: effects on smooth muscle cell proliferation.

Authors:  S Chatterjee
Journal:  Mol Cell Biochem       Date:  1992-04       Impact factor: 3.396

3.  Oxidative modification of low-density lipoproteins and the inhibition of relaxations mediated by endothelium-derived nitric oxide in rabbit aorta.

Authors:  F Plane; K R Bruckdorfer; P Kerr; A Steuer; M Jacobs
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

4.  Abolition of flow-dependent EDRF release before that evoked by agonists in hypercholesterolaemic rabbits.

Authors:  I R Hutcheson; J A Smith; T M Griffith
Journal:  Br J Pharmacol       Date:  1994-09       Impact factor: 8.739

5.  OxLDL induces endothelial dysfunction and death via TRAF3IP2: inhibition by HDL3 and AMPK activators.

Authors:  Anthony J Valente; Anand M Irimpen; Ulrich Siebenlist; Bysani Chandrasekar
Journal:  Free Radic Biol Med       Date:  2014-02-20       Impact factor: 7.376

6.  Rabbit aortic endothelial dysfunction by low-density lipoprotein is attenuated by L-arginine, L-ascorbate and pyridoxine.

Authors:  Yong Ji; Yi Han; Jianxin Diao; Yan Huang; Qi Chen; Albert Ferro
Journal:  Br J Pharmacol       Date:  2003-11-03       Impact factor: 8.739

7.  Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells.

Authors:  J M Heery; M Kozak; D M Stafforini; D A Jones; G A Zimmerman; T M McIntyre; S M Prescott
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

8.  Oxidized low-density lipoprotein and high-density lipoprotein cholesterol modulate coronary arterial remodeling: an intravascular ultrasound study.

Authors:  Satoru Yoneyama; Koh Arakawa; Atushi Yonemura; Kikuo Isoda; Haruo Nakamura; Fumitaka Ohsuzu
Journal:  Clin Cardiol       Date:  2003-01       Impact factor: 2.882

9.  Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells.

Authors:  N Kume; M I Cybulsky; M A Gimbrone
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

10.  Evidence for selective inhibition by lysophosphatidylcholine of acetylcholine-induced endothelium-dependent hyperpolarization and relaxation in rat mesenteric artery.

Authors:  M Fukao; Y Hattori; M Kanno; I Sakuma; A Kitabatake
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.